Pharmaceutical manufacturers of Adenosine

The Ajinomoto Group has advanced its purpose from “Unlocking the power of amino acids to resolve the food and health issues” to “contributing to the well-being of all human beings, our society and our planet with ‘AminoScience’.” We consider well-being to mean health and happiness. Our advanced purpose therefore represents our commitment to achieving two outcomes by 2030 which are connected by food systems: to reduce our environmental impact by 50% and to help extend the healthy life expectancy of 1 billion people.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics. With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Our proprietary products (APIs) cater to the general pharmaceutical sector. We consistently deliver high-quality products and services, utilizing some of the most challenging chemical technologies in the world responsibly and continuously

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Actylis originated in September 2022 through the consolidation of eight well-established specialized manufacturing enterprises and three procurement companies, unified into a singular entity. The companies comprising Actylis are Aceto, A&C, A&C Bio Buffer, Cascade Chemistry, Finar, Interactifs, Islechem, Pharma Waldhof, Syntor Fine Chemicals, Biotron, and Talus. Actylis stands as a prominent producer and provider of essential raw materials and performance components for the Life Sciences, Specialized Chemicals, and Agriscience sectors.

Roche CustomBiotech offers an extensive array of products and services for the diagnostics, biotechnology, and pharmaceutical industries. Our range of offerings includes enzymes, coenzymes, substrates, PCR-based kits for rapid microbiological methods, as well as the Cedex HiRes and Cedex Bio HT Analyzers for monitoring cell growth and fermentation processes.

BD Medical - Pharmaceutical Systems serves as a preferred partner for pharmaceutical and biotechnology firms worldwide. The company offers a wide variety of parenteral drug delivery systems, such as prefilled syringes made of glass and plastic, safety and shielding systems, and advanced drug delivery solutions. These solutions aim to assist pharmaceutical companies in achieving their drug delivery objectives, taking into account factors like drug complexity, viscosity, and dosing volume. BD Medical - Pharmaceutical Systems prioritizes patient-centered innovations and possesses significant technical expertise.

BD operates as a medical technology firm which caters to medical facilities, biomedical researchers, healthcare labs, business and the broader community. BD is involved in the creation, production and distribution of a diverse array of healthcare materials, apparatus, laboratory gear and diagnostic items. BD Medical - Pharmaceutical Systems is the favored associate for the pharmaceutical sector. Through inventive prefilled syringes, self-administration systems, safety mechanisms and needle innovations, we present a wide assortment of options crafted to safeguard, package and deliver pharmaceutical products.

Tianma Pharma Specialty Chemicals, a division of Tianma Pharma Group, was established in 1993 and has emerged as a prominent producer of peptide-related chemicals. These include protected amino acids, such as Fmoc amino acids, Boc amino acids, CBZ amino acids, and amino acids' derivatives, as well as peptide synthesis reagents and pharmaceutical intermediates. The company has also established an R&D center to facilitate innovation. Suzhou Tianma Specialty Chemicals Co., Ltd is a business group listed on the Chinese Stock Market with over two decades of experience delivering tailored services in the realms of paper chemicals, pharmaceutical intermediates, agrochemicals, and nutrition products.

Established in 2018, Jiangsu Synthgene Biotechnology Co., Ltd. is an advanced enterprise engaged in the research and development of technology and products related to fundamental raw materials including nucleosides, nucleotides, diagnostic antigens, and antibodies. With a focus on delivering cost-efficient products and addressing unmet clinical requirements, the company has ventured into the upstream foundational raw materials sector of IVD, mRNA, CGT, and other industries. Additionally, it has set up a high-quality fundamental technology platform to offer comprehensive solutions for advancements in the life sciences sector.

Kaiping Genuine Biochemical Pharmaceutical Co., Ltd is a cutting-edge enterprise that combines research and development, along with production and sales. The forerunner of Genuine, Kaiping Kaili Biochemical Products Factory, was established under the oversight of the Chinese Academy of Sciences in 1992. The factory underwent reform and was renamed Kaiping Genuine Biochemical Pharmaceutical Co., Ltd.” in 2001. Genuine transferred to a new manufacturing facility in 2004, spanning over 120,000 square meters and constructed in accordance with national GMP standards.